« Return to News | Drug Sponsors

Zenobia partners with Alzheimer's Drug Discovery Foundation

Wednesday, August 15, 2012 11:54 AM

Zenobia Therapeutics, a fragment-based discovery company focused on central nervous system (CNS) disease based in San Diego, has formed a strategic partnership to provide Alzheimer's Drug Discovery Foundation (ADDF) researchers access to Zenobia's discovery platform.

Zenobia will provide ADDF researchers with complementary consultation to establish joint research plans that utilize the Zenobia platform and assist in preparation of grant proposals. Once funded, Zenobia will continue to work closely with researchers to evolve the plans as the program progresses. In addition, Zenobia will offer their premier Fragment Library 1 at a reduced price to ADDF researchers.

The Zenobia platform includes: a gene-to-structure platform with in-house cloning, expression and purification in E coli, insect and mammalian cells, a custom fragment library composed of diverse cores suitable for discovery of lead compounds that cross the blood-brain barrier, fragment screening by multiple validated methods and assay development (enzyme, cell and Drosophila). Zenobia will also provide access to their internal medicinal chemistry expertise to optimize the fragments to leads that are potent, selective and optimized for CNS ADME/PK properties.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.